Portrait_default
fermat
Sex: M
Data Quality: 1 star
MS: 21 yrs
Type: Relapsing-Remitting
Sensation: Mild
Overall: None
Cognition: mild
Vision: none
Speech: none
Swallowing: none
Upper limb: none
Walking: none
fermat
Male, 55 years
San Francisco , CA
Primary Condition
MS
Type
Relapsing-Remitting
First symptom
Diagnosis
See more

Treatment charts require Flash. If you have problems installing Flash, visit the FAQ for help.

Get Adobe Flash player

fermat's Natalizumab is for:

  • MS

fermat's side effects of Natalizumab:

fermat's Natalizumab History (Ongoing)
300 mg/15 mL Monthly Aug 01, 2006 - Last Update
Evaluations
Date Dosage MS (Multiple Sclerosis) Perceived effectiveness Side Effects Adherence Burden
Jun 29, 2010 300 mg/15 mL Monthly Led_efficacy_3Led_efficacy_3Led_efficacy_3Led_default ModerateModerateModerateModerate AlwaysAlwaysAlwaysAlways Not at allNot at allNot at allNot at all
Date
Jun 29, 2010
Advice & Tips
First four years uneventful. Last year developed gum ulcerations, initially diagnosed by my dentist as ANUG (acute necrotizing ulcerative gingivitis), with disseminated ulcers on my inner cheeks and gums. Referred to periodontist after failing to respond to conventional first-round treatment. Further treatment and biopsies inconclusive. In late 2009, developed rash on scalp, ears, scrotum. Treated for eczema and other bacterial and fungal infections without effect by dermatologist. In March 2010, rash developed on forehead and torso. Returned to dermatologist, diagnosed as allergic reaction to previous medications. In late March, 2010, developed blistering rash on thighs, toes, forearms, shins, axillae. Tentatively diagnosed as Stephens-Johnson, with biopsy to confirm. Biopsy instead confirmed Bullous Pemphigoid.
Cost
< $25 monthly

About Natalizumab (Prescription Drug)

Natalizumab is a monoclonal antibody given by infusion and used in the treatment of MS and Crohn's disease. It has been shown to slow progression and reduce relapses in MS. It is currently sold under the brand name Tysabri.

Learn more about Natalizumab in our Natalizumab Community Report.

Back to fermat's Profile